A newly discovered hormone named fabkin helps regulate metabolism and may play an important role in the development of both type 1 and type 2 diabetes, according to research led by the Sabri Ülker Center for Metabolic Research at Harvard T.H. Chan School of Public Health. The findings were published in Nature. The study showed blood...
In October, DreaMed Diabetes AI LTD. announced that it received its fourth U.S. Food and Drug Administration (FDA) clearance for its Advisor Pro AI Clinical Decision Support System, which expands the platform’s target population to patients with both type 1 and type 2 diabetes. Advisor Pro is a decision support system cleared to assist healthcare providers...
The gap in the use of insulin pumps and continuous glucose monitors (CGMs) among Black and white Medicare beneficiaries widened from 2017 to 2019, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Reducing health disparities is a major public health goal in the U.S., and these disparities include the use of diabetes technology. All Medicare beneficiaries with type 1 diabetes...
In patients who have diabetes and end-stage kidney disease (ESKD), the rates of severe hypoglycemia crises requiring emergency department visits or hospitalizations are the highest so far reported, according to a nationwide study recently published in Diabetes Care. Researchers led by Rodolfo J. Galindo, MD, FACE, associate professor of medicine at Emory University School of...
COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study in Cell Metabolism. Researchers led by James C. Lo, MD, PhD, an associate professor of medicine in the Weill Center for Metabolic Health and the Cardiovascular Research Institute at Weill Cornell Medicine and a cardiologist at NewYork-Presbyterian/Weill Cornell Medical Center, found that hyperglycemia is common in hospitalized COVID-19 patients and...
During insulin’s first century, treatments and resources for people with diabetes have steadily progressed. So, too, have relationships between the patient and the provider. A recent Endocrine Society-hosted roundtable highlighted this vital connection and how it has evolved through the decades. Leonard Thompson was 14 years old in 1922, and he was dying of type...
Thanks to insulin’s discovery a century ago, diabetes is no longer the death sentence it once was. However, providing care can often be complicated for both in- and outpatient treatment regimens. Potential new models of diabetes care could help ease the burden of both the patients and the providers, whether treatment takes place at home,...
A century after its discovery, insulin’s price tag in the U.S. remains alarmingly high for many people living with diabetes. While experts in healthcare and industry have worked with legislators to address the problem, much more needs to be done so that this lifesaving therapy is available to all who need it. When Leonard Thompson’s...
During insulin’s first century, treatments and resources for people with diabetes have steadily progressed. So, too, have relationships between the patient and the provider. A recent Endocrine Society-hosted roundtable highlighted this vital connection and how it has evolved through the decades. Leonard Thompson was 14 years old in 1922, and he was dying of type...
